Drug Trial Radar · NCT06846541
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,680
Planned (sponsor's estimate)
Start
Jan 8, 2025
Primary completion
Nov 2028
Study completion Nov 2028
Sponsor
- Lead sponsor
- Alumis IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 26, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to answer are: * How safe is taking ESK-001 long-term in people with moderate to severe plaque psoriasis? * Does taking ESK-001 long-term reduce the severity of people's plaque psoriasis? Patients will enter the long-term extension study following completion of one of the parent studies (ESK-001-016 or ESK-001-017) and will receive open-label ESK-001 twice daily for 24 weeks. After 24 weeks, the first 200 patients meeting at least PASI-75 clinical response will be randomly assigned to receive ESK-001 or placebo. At any point during this time, the patients losing the initial clinical response may return to the open-label ESK-001 treatment. Patients who complete Week 48 will return to open-label ESK-001 treatment and they will receive ESK-001 until the end of the study or discontinuation. All the remaining patients not meeting the entry criteria for the randomized withdrawal phase will continue to receive open-label ESK-001 for the remainder of the study. Patients taking part in the study must be men or women aged at least 18 years old and have completed a previous (parent) study of ESK-001 in moderate to severe plaque psoriasis. Patients must consent and agree to: * ensure drug daily compliance until end of study or discontinuation. * visit the clinic for checkups and assessments. * provide blood and urine samples.
Conditions
- Plaque Psoriasis
- Psoriasis (PsO)
- Psoriasis
- Moderate Psoriasis
- Severe Psoriasis
Interventions
Open-Label EnvudeucitinibDrug
Open-Label ESK-001
Blinded EnvudeucitinibDrug
Blinded ESK-001 during Randomized Treatment Withdrawal Period
PlaceboDrug
Placebo during Randomized Treatment Withdrawal Period
Primary outcomes
What the sponsor says the trial is designed to measure.
- To assess the long-term safety and tolerability of ESK-001 throughout the duration of the studyTime frame: Approximately 4 years
Locations
268 sites in 16 countries. Site status is shown where the registry gives one.
Total Dermatology
Birmingham, Alabama
Chandler Clinical Trials
Chandler, Arizona
Alliance Dermatology
Pheonix, Arizona
Scottsdale Clinical Trials
Scottsdale, Arizona
Noble Clinical Research
Tucson, Arizona
Northwest AR Clinical Trials Center PLLC
Rogers, Arkansas
Zenith Research Inc.
Beverly Hills, California
Exalt Clinical Research Inc
Chula Vista, California
California Dermatology and Clinical Research Institute
Encinitas, California
Raoof MD
Encino, California
First OC Dermatology Research Inc
Fountain Valley, California
Marvel Clinical Research LLC
Huntington Beach, California
Long Beach Research Institute
Long Beach, California
Olive View UCLA Education and Research Institute
Los Angeles, California
Dermatology Research Associates
Los Angeles, California
Wallace Medical Group Inc
Los Angeles, California
Northridge Clinical Trials
Northridge, California
Pasadena Clinical Trials
Pasadena, California
Empire Clinical Research Pomona
Pomona, California
Integrative Skin Science and Research
Sacramento, California
Therapeutics Clinical Research
San Diego, California
Southern California Clinical Research
Santa Ana, California
Clinical Science Institute Dermatology Institute
Santa Monica, California
Unison Clinical Trials
Sherman Oaks, California
California Dermatology Institute Thousand Oaks
Thousand Oaks, California
Sunwise Clinical Research LLC
Walnut Creek, California
Clearlyderm Dermatology West Boca Raton
Boca Raton, Florida
Driven Clinical Research
Coral Gables, Florida
FXM Clinical Research Ft. Lauderdale LLC
Fort Lauderdale, Florida
Direct Helpers Research Center
Hialeah, Florida
Jacksonville Center for Clinical Research
Jacksonville, Florida
Glick Skin Institute
Margate, Florida
AppleMed Research Group
Miami, Florida
FAX Pharma Clinical Research Inc
Miami, Florida
FXM Clinical Research Miami LLC
Miami, Florida
Las Mercedes Medical Research
Miami, Florida
Procare Research Center
Miami Gardens, Florida
San Marcus Research Clinic Inc - Miami
Miami Lakes, Florida
Savin Medical Group LLC
Miami Lakes, Florida
FXM Clinical Research Miramar LLC
Miramar, Florida
Showing 40 of 268 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.